What is the recommended tolvaptan dosing schedule for an adult with autosomal dominant polycystic kidney disease and an eGFR of 30–60 mL/min/1.73 m²?

Tolvaptan Dosing for ADPKD with eGFR 30-60 mL/min/1.73 m²

Start tolvaptan at 45 mg in the morning and 15 mg eight hours later, then uptitrate weekly to a target dose of 90 mg morning/30 mg afternoon based on tolerability. 1

Initial Dosing Schedule

The 2025 KDIGO guidelines provide a clear titration pathway for patients with ADPKD, including those with eGFR 30-60 mL/min/1.73 m² 1:

• Week 1 (Initiation): 45 mg upon waking + 15 mg eight hours later
• Week 2+ (Titration): 60 mg AM + 30 mg PM (if tolerated)
• Target dose: 90 mg AM + 30 mg PM (if tolerated)

Uptitration should occur at intervals of at least 1 week, allowing assessment of tolerability before advancing to the next dose level 1.

Evidence Supporting This Approach

The REPRISE trial specifically evaluated tolvaptan in patients with later-stage ADPKD (eGFR 25-65 mL/min/1.73 m²) and demonstrated that tolvaptan slowed eGFR decline by 1.27 mL/min/1.73 m² per year compared to placebo (P<0.001) 2. Importantly, tolvaptan can be continued even when eGFR falls below 25 mL/min/1.73 m² if well tolerated 1.

The hemodynamic profile of tolvaptan does not differ significantly across CKD stages 1-4, though minor reversible GFR decreases may occur in individual patients, likely reflecting reduction in compensatory hyperfiltration 3. This small, reversible eGFR reduction should not deter initiation in patients with eGFR 30-60 mL/min/1.73 m² 1.

Critical Management Points

Fluid Management

• Counsel patients to drink adequate water to replace urinary losses—this is essential for tolerability 1
• Recommend sugar-free, fat-free liquids with low-sodium intake to reduce polyuria 1
• Monitor serum sodium levels (morning samples before tolvaptan dose) to assess adequacy of water intake 1

Sick-Day Planning

Patients must skip tolvaptan doses during:

• Limited water access
• Increased fluid losses (vomiting, diarrhea, fever)
• Activities in warm weather
• Any situation risking volume depletion 1

Dose Adjustments

Consider downtitration or holding tolvaptan with:

• Concurrent strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) 1
• Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice) 1
• Intolerance or side effects (thirst, polyuria, nocturia)
• Elevated liver enzymes 1

Mandatory Monitoring

Liver function tests are non-negotiable:

• Monthly for the first 18 months
• Every 3 months thereafter until discontinuation 1

Hold tolvaptan immediately if:

• AST/ALT ≥3× upper limit of normal (ULN)
• AST/ALT >2× baseline (even if <2× ULN)
• Symptoms suggesting liver injury (fatigue, nausea, right upper quadrant pain, jaundice) 1

Approximately 5.6% of tolvaptan-treated patients develop transaminase elevations >3× ULN (vs. 1.2% on placebo), typically within the first 18 months, which resolve within 1-4 months after cessation 1, 2.

Duration of Therapy

Continue tolvaptan until approaching kidney replacement therapy 1. The medication can be maintained in patients >55 years old and with eGFR <25 mL/min/1.73 m² if well tolerated 1. Evidence shows sustained benefit with long-term use, slowing both kidney volume growth (2.7% reduction) and eGFR decline (1.3 mL/min/1.73 m² per year benefit) 1.

Common Pitfalls to Avoid

1. Don't avoid tolvaptan in patients with eGFR 30-60 mL/min/1.73 m²—the REPRISE trial specifically validated efficacy in this population 2
2. Don't discontinue for small, reversible eGFR decreases—these reflect reduced hyperfiltration, not true kidney injury 1
3. Don't restart tolvaptan after significant hepatotoxicity (ALT/AST >3× ULN with symptoms) unless another explanation is confirmed 1
4. Don't forget to initiate treatment in a hospital setting per FDA labeling for hyponatremia indications, though ADPKD-specific protocols may differ 4